- Home
- ABUS vs CHY Comparison
ABUS vs CHY Comparison
Compare ABUS & CHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- CHY
- Stock Information
- Founded
- ABUS 2005
- CHY 2003
- Country
- ABUS United States
- CHY United States
- Employees
- ABUS N/A
- CHY N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- CHY Investment Managers
- Sector
- ABUS Health Care
- CHY Finance
- Exchange
- ABUS Nasdaq
- CHY Nasdaq
- Market Cap
- ABUS 672.1M
- CHY 792.1M
- IPO Year
- ABUS N/A
- CHY N/A
- Fundamental
- Price
- ABUS $3.08
- CHY $10.57
- Analyst Decision
- ABUS Strong Buy
- CHY
- Analyst Count
- ABUS 4
- CHY 0
- Target Price
- ABUS $5.50
- CHY N/A
- AVG Volume (30 Days)
- ABUS 827.5K
- CHY 128.3K
- Earning Date
- ABUS 05-14-2025
- CHY 01-01-0001
- Dividend Yield
- ABUS N/A
- CHY 10.11%
- EPS Growth
- ABUS N/A
- CHY N/A
- EPS
- ABUS N/A
- CHY N/A
- Revenue
- ABUS $6,403,000.00
- CHY N/A
- Revenue This Year
- ABUS $14.57
- CHY N/A
- Revenue Next Year
- ABUS $15.84
- CHY N/A
- P/E Ratio
- ABUS N/A
- CHY N/A
- Revenue Growth
- ABUS N/A
- CHY N/A
- 52 Week Low
- ABUS $2.63
- CHY $9.97
- 52 Week High
- ABUS $4.72
- CHY $12.16
- Technical
- Relative Strength Index (RSI)
- ABUS 39.99
- CHY 63.64
- Support Level
- ABUS $2.94
- CHY $10.44
- Resistance Level
- ABUS $3.42
- CHY $10.57
- Average True Range (ATR)
- ABUS 0.18
- CHY 0.11
- MACD
- ABUS -0.04
- CHY 0.05
- Stochastic Oscillator
- ABUS 17.72
- CHY 100.00
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About CHY Calamos Convertible and High Income Fund
Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.